Nivolumab + 5-azacytidine

Phase 1/2UNKNOWN

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

AML, Childhood

Conditions

AML, Childhood

Trial Timeline

Nov 29, 2019 → Mar 30, 2024

NCT ID

NCT03825367

About Nivolumab + 5-azacytidine

Nivolumab + 5-azacytidine is a phase 1/2 stage product being developed by Bristol Myers Squibb for AML, Childhood. The current trial status is unknown. This product is registered under clinical trial identifier NCT03825367. Target conditions include AML, Childhood.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03825367	Phase 1/2	UNKNOWN	Nov 29, 2019	Mar 30, 2024	AML, Childhood

Competing Products

20 competing products in AML, Childhood

See all competitors

Product	Company	Stage	Hype Score
LY2940680 + LY2940680	Eli Lilly	Phase 1	33
Panobinostat + Cytarabine + Panobinostat	Novartis	Phase 1	33
Obinutuzumab + MMF + Prednisone + Methylprednisolone + Acetaminophen/ Paracetamol + Diphenhydramine Hydrochloride	Roche	Phase 3	77
Rituximab + Placebo	Roche	Phase 2/3	65
Blinatumomab	Amgen	Phase 2	51
Semaglutide	Novo Nordisk	Approved	84
Temsirolimus + Etoposide + Cyclophosphamide + Methotrexate + Hydrocortisone + Cytarabine	Pfizer	Phase 1	32
Talazoparib + Irinotecan + Temozolomide + Filgrastim + Peg-filgrastim	Pfizer	Phase 1	32
Crizotinib	Pfizer	Phase 1/2	40
carboplatin + irinotecan hydrochloride	Bristol Myers Squibb	Phase 1	32
Vinblastine + Cyclophosphamide + Capecitabine + Nivolumab	Bristol Myers Squibb	Phase 1/2	40
Paxalisib + Opdualag + Irinotecan (drug) + Temozolomide (TMZ)	Bristol Myers Squibb	Phase 1/2	40
Clofarabine incorporated into a 5-drug regimen	Sanofi	Phase 1	32
Brivaracetam Film-coated tablet + Brivaracetam oral solution	UCB	Phase 3	74
Brivaracetam Film-coated tablet + Brivaracetam oral solution	UCB	Phase 3	74
Brivaracetam	UCB	Phase 3	74
Sodium Oxybate	Jazz Pharmaceuticals	Phase 1/2	38
Modified Measles Virus + Modified Measles Virus Lumbar Puncture	Brain Biotech	Phase 1	25
palbociclib isethionate	Brain Biotech	Phase 1	25
Cytarabine + Fludarabine + Hydrocortisone Sodium Succinate + Imetelstat + Leucovorin Calcium + Methotrexate	Geron	Phase 1	28

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved